{'fraction_non_alphanumeric': 0.015482695810564663, 'fraction_numerical': 0.0018214936247723133, 'mean_word_length': 5.742331288343558, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Update on the role of rituximab in kidney diseases and transplant

Introduction: Pathological antibody production by B lymphocytes is characteristic of numerous primary and secondary glomerular diseases of the kidney. Specific and less toxic therapies that target antibody-producing B cells are therefore needed. Based on its property of selectively depleting CD20+ B cells, rituximab is a therapeutic option for antibody-mediated kidney diseases and adds to the existing drug armamentarium for the treatment of a number of these disorders. Areas covered: This article reviews the current use of rituximab in renal disease and transplantation, and includes discussion of the drug's potential role in conditions where traditional treatment has failed. A literature search using PubMed data base was undertaken using search words rituximab and kidney transplantation, glomerulonephritis, antibody production etc. Expert opinon: Rituximab could be a beneficial drug in certain renal diseases and for complications related to kidney transplantation where conventional treatment has not been successful.